Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | BOVARY-pilot: determining HRD with liquid biopsy in ovarian cancer

Alexandre Harlé, PharmD, PhD, Université de Lorraine, Nancy, France, discusses findings from the BOVARY-pilot trial (NCT03881683), which explores liquid biopsy as an alternative to tissue biopsy for homologous recombination deficiency (HRD) assessment in high-grade serous ovarian carcinoma (HSOG). Results showed high concordance between plasma and FFPE tissue samples, with HRD status determined accurately in most cases. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.